Bisantrene (Standard)

[1]Sissi C, et al. DNA-binding preferences of Bisantrene analogues: relevance to the sequence specificity of drug-mediated topoisomerase II poisoning. Mol Pharmacol. 1998 Dec;54 (6) :1036-45.|[2]Yap HY, et al. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar;43 (3) :1402-4.|[3]Wang BS, et al. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[ (4,5-dihydro-1H-imidazole-2-yl) hydrazone] dihydrochloride (bisantrene) . Cancer Res. 1984 Jun;44 (6) :2363-7. |[4]Aksentijevich I, et al. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity. Clin Cancer Res. 1996 Jun;2 (6) :973-80.